China NMPA Product Recall - Hemodialysis equipment

On February 22, 2019, Baxter Medical Products Trading (Shanghai) Co., Ltd. announced a voluntary Class II recall of its hemodialysis equipment, as reported by the National Medical Products Administration (NMPA). This significant action addresses a serious safety concern related to the device's operation. The primary issue identified is the potential for patients, especially those with low body weight (under 25 kg) and ultrafiltration rates below 0.1 kg/h, to experience excessive fluid loss and subsequent hypotension. This risk is amplified if pressure and conductivity alarms are activated. An additional factor contributing to excessive fluid loss is the possibility of leakage in the ultrafilter. The company initiated this voluntary recall under the oversight of the NMPA and the Shanghai Food and Drug Administration, reflecting a commitment to patient safety. A Class II recall indicates that the product may cause temporary or reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, aligning with the identified risks of excessive fluid loss. The required action involves the recall of specific product models, specifications, and batches, details of which are provided in the comprehensive Medical Device Recall Event Report Form. This measure is crucial to prevent potential patient harm.